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Global variation in postoperative mortality and complications 
after cancer surgery: a multicentre, prospective cohort study 
in 82 countries
GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery*
Summary
Background 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early 
outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, 
colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications 
on postoperative mortality.
Methods This was a multicentre, international prospective cohort study of consecutive adult patients undergoing 
surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial 
anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic 
regression determined relationships within three-level nested models of patients within hospitals and countries. 
Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with 
ClinicalTrials.gov, NCT03471494.
Findings Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries 
(high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 
4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in 
high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income 
countries (adjusted odds ratio 3·72, 95% CI 1·70–8·16) and for colorectal cancer in low-income or lower-middle-
income countries (4·59, 2·39–8·80) and upper-middle-income countries (2·06, 1·11–3·83). No difference in 30-day 
mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in 
low-income or lower-middle-income countries (6·15, 3·26–11·59) and upper-middle-income countries (3·89, 
2·08–7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by 
hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven 
to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in 
mortality or postoperative complications.
Interpretation Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation 
of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful 
intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative 
care systems to detect and intervene in common complications.
Funding National Institute for Health Research Global Health Research Unit.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Cancer prevalence and its associated mortality is 
increasing in low-income and middle-income countries 
(LMICs).1 Of the 15·2 million individuals diagnosed 
with cancer worldwide in 2015, 80% needed surgery.2 
Despite this need, fewer than 25% of people worldwide 
have robust access to effective surgical care.3 In tumours 
amenable to resection, surgery offers the best chance of 
cure, particularly in early-stage disease; thus, expanding 
the availability of surgery is likely to yield large improve-
ments in cancer survival in LMICs.4
Direct estimates of the incidence and distribution of 
cancer by stage are absent for many LMICs, and little is 
known about variation in access, quality, and outcomes 
in global cancer care. Breast, colorectal, and gastric 
cancer represent a significant burden of disease across 
income settings and, as such, are clear targets for 
intervention.1,2 Breast cancer is the most common cancer 
worldwide, and a leading cause of cancer-related mor-
bidity and mor tality in LMICs. Addressing inequities in 
breast cancer treatment will be essential in meeting 
gender equality Sustainable Development Goals, as well 
as health and wellbeing objectives. Colorectal cancer 
incidence is rising in LMICs and represents the second 
most common cause of cancer-related death globally. 
Gastric cancer is the third most common cause of 
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cancer-related death in LMICs. These facts were reflected 
in a recent LMIC-led research prioritisation exercise, 
where cancer surgery was identified as a major priority.5
Irrespective of the development status of a country, 
surgery remains the cornerstone of cancer cure and 
palliation. Solid tumours are often untreated in LMICs 
and this carries significant macroeconomic conse-
quences; cumulative gross domestic product losses are 
estimated to be as high as 1·2% for 2016–30.6 Cancer 
resection procedures are often highly invasive, leading to 
postoperative morbidity and mortality. In previous work, 
we identified significant global disparities in surgical 
outcomes, with patients in LMICs two to three times 
more likely to sustain a major complication or to die after 
surgery.7,8 These consequences are devasting for patients 
and their families and, in the context of cancer treat-
ment, complications can lead to long-term morbidity or 
death, increased treatment costs, and delays in adjuvant 
treatment. Rescuing patients who sustain a major 
complication from dying has become an important focus 
of quality improvement in surgery.9 Not only must 
complications be minimised, but the timely recognition 
and management of complications is essential if 
avoidable mortality is to be minimised. Little is known 
about factors contributing to early death and complica-
tions after cancer surgery in LMICs.
This insufficiency of high-quality data limits global 
efforts to improve cancer care. Strategic planning 
mandates detailed and accurate information, so that 
appropriate resources can be allocated and quality 
improvement prioritised. Demographic and clinical data, 
together with details of hospital resources, are needed to 
help refine public health initiatives, treatment strategies, 
and quality improvement interventions. To address these 
issues, we did an international, multicentre, prospective 
cohort study that aimed to determine the variation in 
mortality and complication rates for breast, colorectal, 
and gastric cancers in low-income, middle-income, and 
high-income countries.
Methods
Study design and setting
This international, multicentre, prospective cohort study 
was done according to a published protocol.10 The study 
was designed in a collaborative research prioritisation 
workshop.5 Breast, colorectal, and gastric cancers were 
prioritised on the basis of global prevalence and mortality, 
and relevance to the majority of our collaborators, who are 
predominantly general surgeons and manage these 
cancers regularly. To maximise case ascertainment, ensure 
data quality, and enable engagement across a global 
network, a pragmatic decision was taken not to collect data 
on additional cancer types. All Global Surgery study 
documents, training materials, and language translations 
are available online. Teams of local investigators undertook 
the study and were coordinated by a network of national 
lead investigators. The collaborative network method has 
been described in detail previously.7,8 Any health-care 
facility providing emergency or elective surgery for breast, 
colorectal, or gastric colorectal cancer worldwide was 
eligible to participate.
A UK National Health Service (NHS) Research Ethics 
propor tionate review considered this study exempt 
from formal research registration (South East Scotland 
Research Ethics Service, reference NR/161AB6) because 
it was deemed a clinical audit. Individual centres 
obtained their own audit or institutional approval, 
together with ethical approval as per local regulations.
Research in context
Evidence before this study
We searched for evidence of multinational research assessing 
early outcomes after surgery for three globally common 
cancers (breast, colorectal, and gastric cancer) focusing on 
low-income and middle-income countries (LMICs). 
We searched PubMed, MEDLINE, Google Scholar, and 
ClinicalTrials.gov for articles published between Jan 1, 1990, 
and Aug 1, 2020, using the terms “cancer” OR “malignancy” 
AND “surgery” AND “developing countries” OR “low income” 
OR “middle-income” OR “low and middle-income”, without 
language restrictions. Identified studies largely focused on 
single tumour types and did not compare outcomes across 
different income settings. No studies systematically collected 
comparative data examining outcomes after cancer surgery in 
different income settings.
Added value of this study
To our knowledge, our study is the first to provide 
comprehensive data across income settings on early outcomes 
in patients undergoing surgery for three common cancers. 
We used standardised, validated, and prospective methods to 
gather global, contemporaneous, and comprehensive data. 
Even after case-mix adjustment, patients in LMICs had higher 
postoperative mortality, despite similar complication rates. 
The capacity to rescue patients from death after the 
development of common postoperative complications explains 
a significant part of the disproportionate mortality burden in 
LMICs.
Implications of all the available evidence
Perioperative mortality is disproportionately greater in LMICs, 
which contributes to significantly worse cancer survival. Urgent 
assessment of pragmatic perioperative interventions led by 
investigators in LMICs is needed to avert avoidable mortality 
after the development of common complications after surgery.
For more on the Global Surgery 
resources see globalsurg.org/gs3
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Participants
Investigators included consecutive patients undergoing 
surgery for breast, colorectal, or gastric cancer, from 
one or more 28-day period between April 1, 2018, and 
Jan 31, 2019, with validation performed until April 23, 2019. 
Inclusion criteria were adult patients aged 18 years or 
older; undergoing their first surgical procedure for the 
treatment of one of the three cancers; and requiring 
a skin incision performed under general or neuraxial 
(eg, regional, epidural or spinal) anaesthesia. All patients 
fulfilling the inclusion criteria within the defined period 
were enrolled. A 28-day period was chosen to balance 
sample size requirements and pragmatism for the 
working clinicians who were enrolling patients and 
contributing data.
The inclusion of primary breast, colorectal, and gastric 
cancer was based on global prevalence, potential for 
cure with surgical treatment, and relevance to general 
surgeons working in resource-constrained settings. There 
was an absolute requirement for all cases in the chosen 
period to be included, but no minimum number was set 
to avoid bias against smaller centres. Patients provided 
consent to participate if required by local research 
regulations and could withdraw at any time during the 
study period. Due to potential limitations in preoperative 
diagnosis in some settings, all patients receiving surgical 
treatment for suspected cancer were enrolled. Patients 
subsequently found to have a non-oncological diagnosis 
were excluded from data analysis. Emergency procedures 
were defined as unplanned, non-elective operations. 
Open and mini mally invasive procedures (eg, laparoscopic 
or robotic) were eligible. Patients were excluded if the 
primary pathology was not suspected to be breast, 
colorectal, or gastric cancer; if the pathology was a 
suspected cancer recurrence; or if they were undergoing a 
procedure that did not require a skin incision.
Data collection and validation
Data variables were selected to be objective, standardised, 
easily transcribed, and internationally relevant to 
maximise completeness and accuracy. Local investigators 
uploaded records to a secure website, provided using the 
Research Electronic Data Capture system.11 The lead 
investigator at each site checked the accuracy of all cases 
before data submission. To ensure data quality, real-time 
assessment was done on entry into the database and 
disparities highlighted to the local collaborator for 
immediate review. The submitted data were then 
checked centrally and when missing data were identified, 
the local lead investigator was contacted and asked to 
complete the record. Online data visualisation tools 
aided this process. Once vetted, the record was accepted 
into the dataset for analysis. Records that were vetted 
but remained incomplete were included in the patient 
flow chart, but excluded from analysis.
Patient variables included age, sex, performance status 
according to the Eastern Cooperative Oncology Group, 
physical status according to the American Society of 
Anesthesiologists (ASA) grading system, and smoking 
status. Disease-related variables included cancer type, 
disease stage, timing of surgery (elective vs emergency), 
intent of surgery (curative vs palliative), and use of 
WHO surgical checklist. Presence of preoperative 
perforation or obstruction, and operative approach (open 
or minimally invasive) were also included for gastric and 
colorectal cancers.
Disease stage was defined according to the Essential 
TNM classification of malignant tumours system,12 to 
account for differences in local protocols and availability 
of investigations for preoperative staging. A pragmatic 
view was taken to the confirmation of cancer diagnosis, 
because postoperative pathological examination world-
wide is dependent on the availability of patient and 
health-care resources. To reflect this situation, we 
recorded the basis of cancer diagnosis using a hierarchical 
scale ranging from clinical diagnosis only to pathological 
confirmation (appendix p 7).
Data validation was done in three parts across a repre-
sentative sample of centres, according to a prespecified 
protocol (appendix pp 47–51). First, centres self-reported 
the key processes used to identify and follow up patients 
(appendix p 7). Second, independent validators (ie, 
doctors, nurses, or medical students who were not part 
of the recruiting teams) quantitatively reported case 
ascertainment and sampled data accuracy. Third, 
validators identified any missing eligible patient within 
the local cohort and collected the missing information 
Figure 1: Patient flow chart
8406 patients with breast 
cancer from 313 hospitals 
had surgery and were 
included in analysis 
6215 patients with  colorectal 
cancer from 385 hospitals 
had surgery and were 
included in analysis 
15 958 patients included in analysis across             
82 countries, 428 hospitals, and 836 teams
15 997 patient records across 84 countries, 
435 hospitals, and 846 teams
16 838 patient records across 84 countries, 
437 hospitals, and 853 teams
39 patients excluded due to <90% completion 
of key data variables across two countries
1337 patients with breast cancer 
from 263 hospitals had 
surgery and were included 
in analysis
841 patients excluded
442 patients did not fulfil eligibility criteria
298 duplicate records
51 patients withdrew consent
45 patients did not have surgery
5 records created in error
Articles
4 www.thelancet.com   Published online January 21, 2021   https://doi.org/10.1016/S0140-6736(21)00001-5
for each omission (age, sex, operation urgency, and 
30-day mortality). These data were used to determine 
whether patient data were missing at random.
Outcomes
The primary outcome measures were 30-day mortality 
and 30-day major complication, as defined by Clavien-
Dindo grade III, IV, or V.13 Death was included in the 
definition of major complication and therefore was not a 
competing risk. Capacity to rescue was defined as the 
absolute risk difference of death in patients sustaining a 
complication of surgery. Mortality conditional on major 
complication was analysed post hoc.
The secondary outcome measures were defined in the 
protocol10 and designed to describe cancer care quality. 
They included: 30-day any complication (defined by 
Clavien-Dindo grade I–V); 30-day unplanned reinter-
vention (defined as operative, radiological, or endoscopic 
reintervention any time until 30 days after surgery); 
unplanned readmission to a health-care facility; cancer-
specific complications including seroma (breast), 
anas tomotic leak (gastric and colorectal), surgical site 
infection (all),8 abscess formation (all), and postoperative 
bleed (all); cancer treatment pathways; and hospital-level 
care processes. Patients were assessed at 30 days to 
determine postoperative outcomes, with follow-up 
done in person, by telephone, or by review of medical or 
re-admission records, dependent on local practices.
Sample size
As described in the protocol,10 consideration was given to 
the sample size needed to compare income groups. 
Estimates of 30-day mortality for gastrointestinal cancer 
surgery were determined using data from the GlobalSurg 1 
and 2 studies.7,8 Stratification of results by country income 
group show differences between high-income countries 
and LMICs in both emergency surgery (75 [11·6%] of 644 
vs 59 [27·3%] of 216, respectively) and elective surgery 
(30 [2·0%] of 1501 vs 23 [5·5%] of 416, respectively). An 
indicative sample size calculation using the smaller of 
these estimates suggests around 500 patients per group at 
80% power (2·0% vs 5·5%, α=0·05) or 640 patients per 
group at 90% power would be required to conclude a 
difference in 30-day mortality rate between income groups.
Statistical analysis
Variation across different international health settings was 
assessed by stratifying countries by World Bank country 
group classifications. Differences between World Bank 
tertiles were tested with the Pearson χ² test for categorical 
variables and with the Kruskal-Wallis test for continuous 
variables. Multilevel logistic regression models were 
constructed to account for case mix (diff ering patient, 
disease, and operative characteristics), with population 
stratification by hospital and country of residence incor-
porated as random intercepts with constrained gradients. 
Further post hoc analyses were then performed exploring 
the relationship between primary outcome measures, 
patient factors, and hospital care facilities.
Models were constructed using the following 










Breast 4220 (46·3%) 1319 (48·5%) 2867 (69·4%) 8406 (52·7%)
Colorectal (colon or 
rectum)
4174 (45·8%) 1113 (40·9%) 928 (22·5%) 6215 (38·9%)
Gastric 712 (7·8%) 289 (10·6%) 336 (8·1%) 1337 (8·4%)
Age, years 65·0 (13·4) 58·0 (13·6) 51·9 (12·7) 60·4 (14·4)
Sex
Male 2864 (31·5%) 791 (29·1%) 723 (17·5%) 4378 (27·4%)
Female 6231 (68·4%) 1928 (70·9%) 3406 (82·4%) 11565 (72·5%)
Missing 11 (0·1%) 2 (0·1%) 2 (0%) 15 (0·1%)
ASA grade
I 1148 (12·6%) 739 (27·2%) 1285 (31·1%) 3172 (19·9%)
II 4769 (52·4%) 1474 (54·2%) 2242 (54·3%) 8485 (53·2%)
III 2558 (28·1%) 391 (14·4%) 412 (10·0%) 3361 (21·1%)
IV 217 (2·4%) 42 (1·5%) 36 (0·9%) 295 (1·8%)
V 17 (0·2%) 1 (0%) 10 (0·2%) 28 (0·2%)
Missing 397 (4·4%) 74 (2·7%) 146 (3·5%) 617 (3·9%)
Body-mass index
<18·5 231 (2·5%) 111 (4·1%) 234 (5·7%) 576 (3·6%)
18·5–24·9 3267 (35·9%) 1148 (42·2%) 1511 (36·6%) 5926 (37·1%)
25–30 3079 (33·8%) 882 (32·4%) 1354 (32·8%) 5315 (33·3%)
>30 1773 (19·5%) 470 (17·3%) 867 (21·0%) 3110 (19·5%)
Missing 756 (8·3%) 110 (4·0%) 165 (4·0%) 1031 (6·5%)
>10% weight loss
No 6560 (72·0%) 1813 (66·6%) 2896 (70·1%) 11269 (70·6%)
Yes 1049 (11·5%) 673 (24·7%) 917 (22·2%) 2639 (16·5%)
Missing 1497 (16·4%) 235 (8·6%) 318 (7·7%) 2050 (12·8%)
ECOG performance status
0 5090 (55·9%) 1732 (63·7%) 2136 (51·7%) 8958 (56·1%)
1 2152 (23·6%) 639 (23·5%) 1085 (26·3%) 3876 (24·3%)
2 961 (10·6%) 201 (7·4%) 570 (13·8%) 1732 (10·9%)
3 299 (3·3%) 94 (3·5%) 176 (4·3%) 569 (3·6%)
4 32 (0·4%) 9 (0·3%) 31 (0·8%) 72 (0·5%)
Missing 572 (6·3%) 46 (1·7%) 133 (3·2%) 751 (4·7%)
Smoking
No, never 5363 (58·9%) 1902 (69·9%) 3631 (87·9%) 10896 (68·3%)
Stopped >6 weeks 
ago
1650 (18·1%) 322 (11·8%) 181 (4·4%) 2153 (13·5%)
Yes, current smoker 1174 (12·9%) 347 (12·8%) 170 (4·1%) 1691 (10·6%)
Missing 919 (10·1%) 150 (5·5%) 149 (3·6%) 1218 (7·6%)
Diabetes
No 7594 (83·4%) 2179 (80·1%) 3100 (75·0%) 12873 (80·7%)




895 (9·8%) 324 (11·9%) 422 (10·2%) 1641 (10·3%)
Insulin dependent 279 (3·1%) 120 (4·4%) 191 (4·6%) 590 (3·7%)
Missing 129 (1·4%) 56 (2·1%) 373 (9·0%) 558 (3·5%)
(Table continues on next page)
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in previous studies were accounted for; demographic 
variables were included in model exploration; population 
stratification by hospital and country of residence was 
incorporated as random effects; all first-order interactions 
were checked and included in final models if found to be 
influential (reaching statistical significance or resulting 
in a 10% or greater change in the odds ratio (OR) of the 
explanatory variable of interest); final model selection 
was done using a criterion-based approach by minimising 
the Akaike information criterion and discrimination 
deter mined using the C-statistic (area under the receiver 
operator curve). Effect estimates are presented as ORs 
and 95% CIs. The variance explained at each level of 
multilevel models was determined.14 The conditional 
pseudo R² was defined as the sum of the variance 
components of fixed and all random effects divided by 
total variance. The variance explained by each component 
(marginal pseudo R²) was expressed as a proportion of 
the conditional pseudo R².
Mediation analysis was performed by three-way 
decomposition of total effects into direct, indirect, and 
interactive effects.15 The mediators examined were at the 
level of the hospital, defined as the presence or absence 
of postoperative care infrastructure, and it was assumed 
that there was no causal relationship between these and 
patient-level covariates. Similarly, no mediator-outcome 
confounders were specified. Uncertainty was determined 
using bootstrap resampling (5000 draws) and CIs 
constructed using percentiles.
Quantities of interest were calculated from logistic 
regression models for different covariate levels (patient 
and disease characteristics). Absolute risk differences 
were calculated, and CIs determined using bootstrap 
resampling. The number needed to treat to benefit was 
defined as the reciprocal of the absolute risk difference.
All analyses were done using R (version 3.6.3), using 
the finalfit, tidyverse, and lme4.
This trial was prospectively registered with 
ClinicalTrials.gov, NCT03471494.
Role of the funding source
National Institute for Health Research (NIHR) Global 
Health Research Unit Grant (NIHR 17–0799) funded 
hub development in a subset of contributing countries. 
The views expressed are those of the authors and 
not necessarily those of the NHS, the NIHR or the 
UK Department of Health and Social Care. The funder of 
the study had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
Article. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between April 1, 2018, and Jan 31, 2019, 16 838 patient 
records were submitted for analysis. 880 (5·2%) did not 
fulfil the inclusion criteria, leaving 15 958 records for 
the final analysis (figure 1). These patients were from 
428 hospitals, across 82 countries—22 in Africa, 17 in 
Asia, 30 in Europe, five in North America, two in Oceania, 
and six in South America.
On stratification by World Bank country income 
groups, 9106 (57·1%) patients were from high-income 
countries, 2721 (17·0%) from upper-middle-income 
countries, and 4131 (25·9%) from low-income or lower-
middle-income countries (table; appendix p 2). Patients 
from upper-middle-income countries and low-income or 
lower-middle-income countries were younger, more 
likely to have lost weight, and had fewer comor bidities 
compared with patients from high-income countries. 
Missingness was low and no patterns were seen when 
comparing included and missing data (appendix pp 2–3).
Overall, 8406 (52·7%) patients had surgery for 
breast cancer, 6215 (38·9%) for colorectal cancer, and 
1337 (8·4%) for gastric cancer (figure 1). The distribution 
of cancer type, unadjusted mortality, and complication 
rates across country income group are shown in figure 2.
The proportion of patients with later-stage disease who 
had surgery was greater in upper-middle-income countries 
and low-income or lower-middle-income countries for all 
three cancer groups (figure 3; appendix p 8). There was a 
strong positive correlation between cancer stage and 
performance status for patients with gastric cancer, and a 
weaker relationship in patients with breast and colorectal 
cancer (appendix pp 9–14). No strong relationship between 
operative risk (ASA grade) and cancer stage was seen.
30-day mortality was higher for gastric cancer in the 
low-income or lower-middle-income group (33 [10·1%] 
of 326) and for colorectal cancer in the upper-middle-
income group (47 [4·3%] of 1102) and low-income or 









(Continued from previous page)
HIV tested
No 8650 (95·0%) 1626 (59·8%) 2118 (51·3%) 12394 (77·7%)
Yes, negative 404 (4·4%) 1067 (39·2%) 2001 (48·4%) 3472 (21·8%)
Yes, positive 9 (0·1%) 26 (1·0%) 12 (0·3%) 47 (0·3%)
Missing 43 (0·5%) 2 (0·1%) 0 45 (0·3%)
Distance from hospital to home, km
<10 3497 (38·4%) 677 (24·9%) 575 (13·9%) 4749 (29·8%)
10 to 19·9 1798 (19·7%) 617 (22·7%) 673 (16·3%) 3088 (19·4%)
20 to 49·9 1756 (19·3%) 479 (17·6%) 768 (18·6%) 3003 (18·8%)
50 to 100 738 (8·1%) 195 (7·2%) 514 (12·4%) 1447 (9·1%)
>100 576 (6·3%) 439 (16·1%) 1409 (34·1%) 2424 (15·2%)
Missing 741 (8·1%) 314 (11·5%) 192 (4·6%) 1247 (7·8%)
Numbers are n (%) or mean (SD). High income included 31 countries and 241 hospitals. Upper-middle income included 
23 countries and 81 hospitals. Lower-middle income or low income included 28 countries and 106 hospitals. The total 
column therefore includes 82 countries and 428 hospitals. For patient characteristics by cancer type, see appendix p 2. 
ASA=American Society of Anesthesiologists. ECOG=Eastern Cooperative Oncology Group. 
Table: Patient characteristics by country income group
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compared with the high-income group (gastric 27 [3·8%] 
of 702; colorectal 94 [2·3%] of 4142; figure 3; appendix 
p 20). However, the proportion of patients with a major 
complication or any complication was similar across all 
income groups.
Outcomes were adjusted in three-level models 
accounting for patient and disease factors nested within 
hospitals and country of treatment (figure 4; appendix 
pp 22–38). Higher 30-day mortality was seen in gastric 
cancer in low-income or lower-middle-income countries 
(adjusted OR [aOR] 3·72, 95% CI 1·70–8·16) and in 
colorectal cancer in upper-middle-income countries 
(2·06, 1·11–3·83) and low-income or lower-middle-
income countries (4·59, 2·39–8·80; figure 4). No differ-
ence in mortality was seen in breast cancer.
The proportion of patients sustaining a major 
complication or any complication in these adjusted 
analyses was similar across country income groups, 
with weak evidence of fewer major complications after 
breast surgery in the upper-middle-income group 
(figure 4).
No statistical interactions were seen between patient 
factors and country income group for mortality or compli-
cations; for example, the effect of age, body-mass index, 
and ASA grade on outcomes did not differ by country 
income group.
Given similar complication rates across country income 
groups, we did an analysis defined post hoc to examine 
factors predicting mortality after major complications in 
colorectal and gastric cancer, to determine where capac-
ities to rescue patients might exist.
The proportion of patients sustaining a major 
complication who subsequently died was higher in 
upper-middle-income and low-income or lower-middle-
income countries compared with high-income countries, 
in both unadjusted (figure 3) and adjusted analyses 
(appendix p 4). The relationship between mortality and 
country income group was consis tent across cancer stage 
of presentation, except for stage IV gastric cancer, where 
mortality was high across all country income groups 
(appendix p 4). Similarly, the proportion of patients 
sustaining complications across country income groups 
was unchanged after stratification by stage of presentation 
(appendix p 4).
The pattern of complications occurring within cancer 
types was broadly similar across country income groups 
(appendix p 5). No systematic differences in the types of 
complications being sustained (eg, bleeding, infection) 
were seen in different country income groups.
In a model accounting for patient factors and clustering 
by country and hospital, patients in upper-middle-income 
(aOR 3·89, 2·08–7·29) and low-income or lower-middle-
income (6·15, 3·26–11·59) groups were more likely to 
die after a major complication compared with the high-
income group (figure 5; appendix p 43). Patient perfor-
mance status and emergency surgery were strong 
predictors of death after major complication. Although 
patients with stage IV cancer had a greater probability 
of dying after major complication, stage I to III cancer 
was not associated with an excess mortality when 
accounting for other variables in the model. A sensitivity 
analysis using final pathological staging, as opposed to 
preoperative clinical staging, showed similar findings 
(appendix pp 15–16).
In a four-level model of patients nested in hospitals, 
countries, and World Bank income groups, 60% of the 
variation in outcome captured by the model (pseudo 
R² 0·42) was explained by patient or disease factors, with 
the remaining 40% explained by hospital, country, and 
country income group factors.
We assessed hospital facilities and processes to 
determine relationships with excess mortality after 
Figure 2: Patients and outcomes by cancer type and country income group
Data are for 15 958 patients from 82 countries and 428 hospitals. Crude outcome rates are shown for 30-day mortality, 30-day major complication (Clavien-Dindo grade ≥III), and 30-day any 
complication.
Overall 
Breast cancer Colorectal cancer Gastric cancer
High income 
Upper-middle income 
Low or lower-middle income 
8406 patients with breast cancer from 313 hospitals
Mortality 16 (0·2%) of 8334
Major complication 496 (5·9%) of 8366
Any complication 3024 (36·1%) of 8366
6215 patients with colorectal cancer from 385 hospitals
Mortality 204 (3·3%) of 6149
Major complication 889 (14·4%) of 6181
Any complication 2934 (47·4%) of 6187
1337 patients with gastric cancer from 263 hospitals
Mortality 71 (5·4%) of 1311
Major complication 192 (14·5%) of 1321
Any complication 612 (46·3%) of 1321
4220 patients from 156 hospitals 
Mortality 4 (0·1%) of 4207
Major complication 218 (5·2%) of 4215
Any complication 1346 (31·9%) of 4215
4174 patients from 225 hospitals
Mortality 94 (2·3%) of 4142
Major complication 590 (14·2%) of 4162
Any complication 1977 (47·5%) of 4165
712 patients from 147 hospitals 
Mortality 27 (3·8%) of 702
Major complication 105 (14·8%) of 709
Any complication 311 (43·9%) of 709
1319 patients from 64 hospitals
Mortality 2 (0·2%) of 1295
Major complication 61 (4·7%) of 1306
Any complication 477 (36·5%) of 1306
289 patients from 44 hospitals
Mortality 11 (3·9%) of 283
Major complication 26 (9·2%) of 284
Any complication 142 (50·0%) of 284
1113 patients from 71 hospitals
Mortality 47 (4·3%) of 1102
Major complication 125 (11·3%) of 1107
Any complication 449 (40·5%) of 1109
928 patients from 89 hospitals
Mortality 63 (7·0%) of 905
Major complication 174 (19·1%) of 912
Any complication 508 (55·6%) of 913
2867 patients from 93 hospitals
Mortality 10 (0·4%) of 2832
Major complication 217 (7·6%) of 2845
Any complication 1201 (42·2%) of 2845
336 patients from 72 hospitals
Mortality 33 (10·1%) of 326
Major complication 61 (18·6%) of 328
Any complication 159 (48·5%) of 328
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major complications. Hospitals in high-income (n=232), 
upper-middle-income (n=72) and low-income or lower-
middle-income (n=95) groups were sampled. Hospitals 
in upper-middle-income and low-income or lower-
middle-income groups were less likely to have post-
operative care infrastructure (designated post operative 
recovery areas, consistently available critical care 
facilities, and an available and working CT) and cancer 
care pathways (tumour board, oncology services, and 
palliative care services; appendix pp 41–42).
The association between country income group and 
30-day mortality was examined in a three-way decom-
position mediation model of postoperative care infra-
structure (figure 5; appendix p 44). No interaction was 
found between this mediator and country income 
group. A significant proportion of the excess mortality 
after major complication was mediated by the absence 
of postoperative care infrastructure in low-income or 
lower-middle-income (aOR 1·19, 95% CI 1·01–1·42; 
20%) and upper-middle-income (1·19, 1·01–1·42; 22%) 
groups. The absolute risk differences for 30-day 
mortality after major complication with and without 
consistently available postoperative care infrastructure 
were examined for common patient covariates (figure 5; 
appendix p 45). The presence of postoperative care 
infrastructure was associated with fewer deaths in both 
the low-income or lower-middle-income group (seven 
to ten fewer deaths per 100 major complications, 
number needed to treat 10–14) and the upper-middle-
income group (five to eight fewer deaths per 100 major 
complications, number needed to treat 13–20). Cancer 
care pathways were not shown to mediate any 
association with 30-day mortality.
In 265 hospitals in 69 countries randomly selected 
for validation (1060 hospital-weeks of data collection), 
3805 patients fulfilled inclusion criteria compared with 
3669 (96·4%) in the primary dataset (appendix p 47). 
Accuracy was high for the validated continuous predictor 
(Pearson’s correlation coefficient 0·99; appendix p 50). 
Agreement for categorical predictors was good (sex, 
T stage, urgency, and intent; Cohen’s κ coefficients 
>0·75; appendix p 51) and lower for N stage (κ 0·67). 
Agreement was very good for 30-day mortality (κ 0·89) 
and good for 30-day major complication (κ 0·63).
Discussion
Differences in early cancer outcomes in LMICs 
compared with high-income countries are often 
attributed to the advanced stage of presentation, 
together with an absence of access to cancer-specific 
treatments. In this pro spective, international cohort 
study of 15 958 patients in 82 countries undergoing 
surgery for breast, colorectal, and gastric cancer, we 
show that 30-day postoperative mortality is four-times 
higher in resource-limited settings, despite patients 
experiencing similar major complication rates. 
Although patient factors partially explained the higher 
postoperative mortality rate in LMICs, health system 
factors, including access to postoperative monitoring, 
emergent imaging, and critical care facilities also 
appeared key, resulting in an insufficiency of capacity to 
rescue after major com plications. This excess mortality 
after cancer surgery will hamper cancer control efforts 
in LMICs, and prevent cancer patients, communities, 
and economies from realising the benefits of cancer-
specific treatments.
Figure 3: Stage of presentation (A), 30-day mortality (B), and 30-day complications (C) by cancer and country 
income group
(A) Proportion of patients enrolled by cancer stage by country income group. (B) Proportion of patients dying or 
sustaining a major complication or any complication by day 30 after surgery stratified by country income group. 
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According to Global Cancer Observatory data, cancer is 
a leading cause of death and disability worldwide, 
exerting substantial economic effects in countries at all 
stages of development,16 with a dis pro portionate burden 
of disease now emerging in LMICs.2 Surgery is 
fundamental to the treatment of solid cancers across all 
income settings, acting as a pivotal com ponent of 
multidisciplinary care, together with imaging, pathology, 
chemoradiotherapy, and palliation. Effective surgical care 
plays a crucial role in the prevention of death from 
cancer,2 and requires systems of the highest quality 
throughout the preoperative and postoperative periods.3 
If the opportunity to strengthen surgical cancer systems 
is not taken, an estimated US$6·2 trillion in gross 
domestic product will be lost by 2030.2
Mortality reported in our study across LMICs for both 
gastric (7·2%) and colorectal (5·5%) cancer were higher 
than current global estimates.17 Existing perioperative 
mortality rates in the literature are limited by the absence 
of standardised reporting and risk stratification, and are 
often derived from small, single-centre studies. The 30-day 
mortality in our study was similar to that in our previous 
multicentre observational cohorts.7,8 Across gastric and 
colorectal cancers, variation in 30-day mor tality between 
high-income countries and LMICs was shown after both 
emergency (7·1% vs 18·0%, respectively) and elective 
(1·9 vs 4·0%, respectively) surgery.
There are well described factors that could contribute 
to an early excess mortality after cancer surgery. Locally 
advanced or metastatic cancer is a common initial 
presentation in LMICs, due in part to reduced access to 
timely and affordable surgical services.2 Delays in 
presen tation result in poorer survival through a 
combination of cancer progression,18 cancer-related 
cachexia,19 and the consequences of emergency 
presentation. Achieving early detection and treatment 
through cancer screening initiatives is important, and 
often the focus of public health initiatives and funding.20 
However, in this study we show that excess mortality 
after cancer surgery in LMICs is only partly explained 
by the later presentation of disease. We have shown an 
excess in postoperative mortality despite similar rates 
and patterns of com plications. The importance of 
rescuing patients from common complications is now 
well established with variation described globally.21 To 
our knowledge, our study is the first to identify capacity 
to rescue as an important early determinant of 
outcomes from cancer surgery in resource-restricted 
Figure 4: Multilevel logistic regression-adjusted outcomes by World Bank country income group
Models were built incorporating patient and disease factors specific to each cancer. Univariable, full multivariable, parsimonious multivariable, and multilevel (patient, hospital, country) models for 
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settings. Furthermore, we have shown an association 
between the consistent presence of postoperative care 
infrastructure and lower mortality rates after major 
complications. The capacity to rescue patients is likely 
to limit expected reductions in mortality from current 
global development funds and multilateral investments 
in cancer control. Better perioperative care systems to 
detect and intervene in common complications are 
essential if early death after cancer surgery is to be 
reduced.
A major strength of this study is its prospective design 
and deep patient-level and hospital-level data collected 
simultaneously from a wide breadth of global settings. 
More than 100 variables were included, making it one of 
the richest datasets in this area, to our knowledge. The 
use of the Essential TNM system, together with standard 
TNM 8 classifications, make meaningful comparisons of 
cancer stage possible in settings with limited access to 
imaging and pathological services.12 The assessment of 
cancer stage, treatment, and outcome was standardised, 
Figure 5: Capacity to rescue from major complication 
(A) Multilevel logistic regression model for predictors of death after major complication in colorectal and gastric cancer. Box size proportional to group size (n). (B) Three-way decomposition 
mediation model of the proportion of the effect of country income group on 30-day mortality mediated by postoperative care infrastructure (the consistent presence of a designated postoperative 
recovery area, the availability of critical care facilities, and the existence of a working CT scanner). (C) Proportion of 30-day mortality variation explained at the level of patient or disease, hospital, 
country, and country income group, in patients with colorectal or gastric cancer who died after major complication. The variance explained at each of the four levels of the model (marginal pseudo R²) 
is expressed as a proportion of the total variance explained (conditional pseudo R²). (D) Absolute risk difference for 30-day mortality after major complication in the presence of consistently available 
postoperative care infrastructure. Estimates for age 55 years, ECOG performance status 1, ASA grade 2, cancer stage II, and elective surgery. WB=World Bank. OR=odds ratio. ECOG=Eastern Cooperative 
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and training provided through an online platform. Data 
quality was ensured though collaborator-facing web 
applications and real-time data entry quality assurance. 
An independent validation study verified data accuracy 
and case ascertainment. Quantification of surgical 
cancer care in resource-limited settings has been 
hindered by an insufficient amount of high-quality 
data.4,17,22 This study therefore contributes to closing this 
knowledge gap and allows meaningful comparison from 
multiple income settings with accurate case-mix 
adjustment.
Limitations of this study include looking at outcomes 
only in the 30 days after surgery. Oncological outcomes 
are essential in capturing the effectiveness of cancer 
treatments, including surgery, and these outcomes are 
poorly captured and understood in resource-limited 
settings.2,4 Disease-free and overall survival after surgery 
are likely to be significantly lower in LMICs, for many of 
the reasons described in this study, including the later 
stage disease across included cancers. The effect of 
delayed surgery in life-years lost for stage I–III disease is 
well described in high-income countries;23 however the 
impact of this in global settings is less clear. The current 
study will be extended to capture longer-term outcomes 
and other cancers in the future, which should add 
significantly to the picture of global surgical cancer care 
we have provided here.
Only patients undergoing primary surgery for breast, 
colorectal, or gastric cancers were included in our study, 
and therefore outcomes in patients receiving non-surgical 
care were not examined. Furthermore, the relationship 
between outcomes and hospital-level facilities were 
associations. Hospitals with CT and critical care facilities 
are likely to have other differences in infrastructure and 
processes that might contribute to better outcomes. 
Although we provide several important measures of 
hospital facilities (appendix pp 41–42), further detailed 
analyses of these data are ongoing. Finally, the substantial 
economic and financial costs to patients undergoing 
cancer treatment are known to be significant, but were 
not measured.
Reducing early mortality after surgery is key to 
improving cancer outcomes and achieving Universal 
Health Coverage for non-communicable diseases 
worldwide. The Lancet Commission on Global Cancer 
Surgery identified the key requirements to scale up 
surgical cancer services by 2030.3 Improvements in the 
provision of cancer care remain essential if Sustainable 
Development Goals are to be met. Yet, detailed global 
information supporting focused initiatives to develop 
infrastructure, improve quality, and imple ment effective 
interventions remains limited. Although complete 
analysis of the patient pathway was not possible within 
this study, we identified multiple components of the 
surgical health system and patient-level risk factors that 
could be targeted for further study and intervention. 
High-quality perioperative care requires appropriate 
recovery and ward space, a sufficient number of well 
trained staff, the use of early warning systems, and ready 
access to imaging, operating theatre space, and critical 
care facilities to deal with complications when they 
occur—the delivery of which is even more challenging in 
the present COVID-19 pandemic.24
Access to cancer surgery is an important barrier to safe 
and effective care for people with cancer in LMICs.25 
Improved access comes with further opportunities for 
optimisation of individual patients through, for instance, 
nutritional interventions and neoadjuvant therapies. 
Addressing these factors with high-quality interventional 
trials to build a global evidence base for the delivery of 
safe cancer surgery is likely to have significant effect and 
improve cancer survival.
This study has produced a unique prospective dataset 
of patients undergoing breast, colorectal, and gastric 
cancer surgery worldwide. Future research should focus 
on the detailed characterisation of perioperative care 
processes and the implementation of strategies to both 
reduce complication rates, and to rescue patients from 
complications when they do occur. Policy makers 
worldwide must balance investments in the early detec-
tion and treatment of cancer with the simultaneous 
improvement in safe perioperative care. Without these 
investments, mortality gains in cancer control will not be 
fully realised.
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